MXPA00012796A - Vacuna de salmonella. - Google Patents
Vacuna de salmonella.Info
- Publication number
- MXPA00012796A MXPA00012796A MXPA00012796A MXPA00012796A MXPA00012796A MX PA00012796 A MXPA00012796 A MX PA00012796A MX PA00012796 A MXPA00012796 A MX PA00012796A MX PA00012796 A MXPA00012796 A MX PA00012796A MX PA00012796 A MXPA00012796 A MX PA00012796A
- Authority
- MX
- Mexico
- Prior art keywords
- bacteria
- flagellin
- vaccine
- salmonella
- flagella
- Prior art date
Links
- 229940124842 Salmonella vaccine Drugs 0.000 title description 2
- 241000894006 Bacteria Species 0.000 claims abstract description 73
- 229960005486 vaccine Drugs 0.000 claims abstract description 66
- 241000607142 Salmonella Species 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 108010040721 Flagellin Proteins 0.000 claims description 71
- 108090000623 proteins and genes Proteins 0.000 claims description 62
- 210000003495 flagella Anatomy 0.000 claims description 48
- 241001465754 Metazoa Species 0.000 claims description 46
- 230000000890 antigenic effect Effects 0.000 claims description 31
- 208000015181 infectious disease Diseases 0.000 claims description 26
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 23
- 230000035772 mutation Effects 0.000 claims description 18
- 206010039438 Salmonella Infections Diseases 0.000 claims description 14
- 206010039447 salmonellosis Diseases 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 8
- 230000002238 attenuated effect Effects 0.000 claims description 7
- 230000008436 biogenesis Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 230000001717 pathogenic effect Effects 0.000 claims description 5
- 241001467018 Typhis Species 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 231100000255 pathogenic effect Toxicity 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000000813 microbial effect Effects 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 description 20
- 102100026711 Metalloreductase STEAP2 Human genes 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 18
- 241000287828 Gallus gallus Species 0.000 description 15
- 241000282412 Homo Species 0.000 description 14
- 235000013330 chicken meat Nutrition 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 238000002255 vaccination Methods 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 239000006161 blood agar Substances 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 241000282887 Suidae Species 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000004520 agglutination Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000002703 mutagenesis Methods 0.000 description 6
- 231100000350 mutagenesis Toxicity 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 238000000729 Fisher's exact test Methods 0.000 description 4
- 101100238784 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) mtfA gene Proteins 0.000 description 4
- 208000021017 Weight Gain Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 238000013401 experimental design Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 244000144977 poultry Species 0.000 description 4
- 235000013594 poultry meat Nutrition 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 101001072091 Homo sapiens ProSAAS Proteins 0.000 description 3
- 102100036366 ProSAAS Human genes 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 244000144980 herd Species 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 241001138501 Salmonella enterica Species 0.000 description 2
- 241000607356 Salmonella enterica subsp. arizonae Species 0.000 description 2
- 241000607662 Salmonella enterica subsp. enterica serovar Abortusequi Species 0.000 description 2
- 241000392514 Salmonella enterica subsp. enterica serovar Dublin Species 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- NKAAEMMYHLFEFN-UHFFFAOYSA-M monosodium tartrate Chemical compound [Na+].OC(=O)C(O)C(O)C([O-])=O NKAAEMMYHLFEFN-UHFFFAOYSA-M 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000011886 postmortem examination Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000017105 transposition Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101000822797 Naja naja Long neurotoxin 5 Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 101100099821 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cbs-1 gene Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 235000012364 Peperomia pellucida Nutrition 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241000773293 Rappaport Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000607683 Salmonella enterica subsp. enterica serovar Pullorum Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000007692 polyacrylamide-agarose gel electrophoresis Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99204564 | 1999-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA00012796A true MXPA00012796A (es) | 2002-05-23 |
Family
ID=8241112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA00012796A MXPA00012796A (es) | 1999-12-28 | 2000-12-19 | Vacuna de salmonella. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20010021386A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1112747B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5745731B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE269104T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU783508B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0006291B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2329676A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60011560T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1112747T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2222152T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HU226192B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA00012796A (cg-RX-API-DMAC7.html) |
| PL (1) | PL206377B1 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1112747E (cg-RX-API-DMAC7.html) |
| TR (1) | TR200401569T4 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4751570B2 (ja) * | 2002-09-11 | 2011-08-17 | 東レ・ダウコーニング株式会社 | オルガノポリシロキサン変性多糖類およびその製造方法 |
| PL2066339T3 (pl) | 2006-09-18 | 2015-02-27 | Univ Arkansas | Kompozycje i sposoby zwiększania odpowiedzi immunologicznych |
| US20080260777A1 (en) * | 2007-04-19 | 2008-10-23 | Sotomayor Konky | Composition and method for controlling intestinal pathogenic organisms |
| US7935355B2 (en) * | 2007-04-19 | 2011-05-03 | Nutritional Health Institute Laboratories, Llc | Composition and method for controlling intestinal pathogenic organisms |
| CA2704457A1 (en) * | 2007-10-30 | 2009-05-07 | Walter Bottje | Compositions and methods of enhancing immune responses to flagellated bacterium |
| AU2008318357B2 (en) | 2007-11-01 | 2015-01-22 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to eimeria |
| WO2009062112A2 (en) | 2007-11-09 | 2009-05-14 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as antimicrobials |
| DK2525817T3 (en) | 2010-01-21 | 2017-10-02 | Univ Arkansas | Vaccine vectors and methods for enhancing immune responses |
| NZ718006A (en) | 2010-06-09 | 2017-06-30 | Univ Arkansas | Vaccine and methods to reduce campylobacter infection |
| KR101449417B1 (ko) | 2012-06-20 | 2014-10-27 | 한국외국어대학교 연구산학협력단 | 살모넬라 엔테리카의 박테리오파아지 및 그 용도 |
| RU2683027C2 (ru) | 2012-12-20 | 2019-03-26 | Заклад Бадавчо-Вдроженёвы Осьродка Сальмонельля "Иммуноляб" Сп. З О.О. | Поливалентная иммунизирующая и/или терапевтическая композиция для применения при бактериальных инфекциях или пищевом отравлении, в частности сальмонеллёзе, способ получения этой композиции, её применение и вакцина, содержащая эту композицию |
| CA2900644C (en) | 2013-02-14 | 2023-03-14 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection |
| WO2014164607A1 (en) | 2013-03-11 | 2014-10-09 | The Brigham And Women's Hospital, Inc. | Vibro-based delivery system and immune suppression |
| AU2014239557B2 (en) | 2013-03-15 | 2019-01-03 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to enteric pathogens |
| TWI843057B (zh) | 2016-05-03 | 2024-05-21 | 阿肯色州大學董事會 | 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法 |
| CN111374094B (zh) * | 2020-03-02 | 2022-04-19 | 扬州大学 | 驴源马流产沙门氏菌经皮下致非妊娠期小鼠子宫感染模型的建立方法 |
| CN118773056B (zh) * | 2024-07-10 | 2025-07-08 | 山东省滨州畜牧兽医研究院 | 一种马流产沙门氏菌灭活疫苗 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1109179A (en) * | 1964-09-30 | 1968-04-10 | Nat Res Dev | Improvements relating to typhoid and paratyphoid vaccines |
| ES2060580T3 (es) * | 1986-03-11 | 1994-12-01 | Shionogi & Co | Adn que tiene una secuencia adn codificante de la proteina flagelina y vector que la contiene. |
| DE68922394T2 (de) * | 1988-05-05 | 1995-10-05 | Praxis Biolog Inc | Rekombinante vakzine von flagellin. |
| US6130082A (en) * | 1988-05-05 | 2000-10-10 | American Cyanamid Company | Recombinant flagellin vaccines |
| JP3436756B2 (ja) * | 1988-12-19 | 2003-08-18 | アメリカン・サイアナミド・カンパニー | 髄膜炎菌のクラスｉの外膜タンパク質のワクチン |
| DE69528450T2 (de) * | 1994-02-18 | 2003-01-23 | Solidose, L.L.C. | Impfung von tieren mit getrockneten pelletierten biologischen materialien |
| GB9621091D0 (en) * | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
| US6190669B1 (en) * | 1998-05-13 | 2001-02-20 | University Of Maryland, Baltimore | Attenuated mutants of salmonella which constitutively express the Vi antigen |
-
2000
- 2000-12-19 DE DE60011560T patent/DE60011560T2/de not_active Expired - Lifetime
- 2000-12-19 TR TR2004/01569T patent/TR200401569T4/xx unknown
- 2000-12-19 ES ES00204630T patent/ES2222152T3/es not_active Expired - Lifetime
- 2000-12-19 DK DK00204630T patent/DK1112747T3/da active
- 2000-12-19 MX MXPA00012796A patent/MXPA00012796A/es active IP Right Grant
- 2000-12-19 PT PT00204630T patent/PT1112747E/pt unknown
- 2000-12-19 EP EP00204630A patent/EP1112747B1/en not_active Expired - Lifetime
- 2000-12-19 AT AT00204630T patent/ATE269104T1/de active
- 2000-12-20 JP JP2000387225A patent/JP5745731B2/ja not_active Expired - Fee Related
- 2000-12-21 AU AU72453/00A patent/AU783508B2/en not_active Ceased
- 2000-12-27 CA CA002329676A patent/CA2329676A1/en not_active Abandoned
- 2000-12-27 HU HU0005010A patent/HU226192B1/hu not_active IP Right Cessation
- 2000-12-27 BR BRPI0006291-0A patent/BR0006291B1/pt not_active IP Right Cessation
- 2000-12-27 US US09/749,025 patent/US20010021386A1/en not_active Abandoned
- 2000-12-28 PL PL344851A patent/PL206377B1/pl not_active IP Right Cessation
-
2007
- 2007-10-30 US US11/980,864 patent/US20080069843A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK1112747T3 (da) | 2004-10-25 |
| PT1112747E (pt) | 2004-10-29 |
| EP1112747B1 (en) | 2004-06-16 |
| DE60011560D1 (de) | 2004-07-22 |
| BR0006291B1 (pt) | 2014-02-18 |
| DE60011560T2 (de) | 2005-08-18 |
| PL206377B1 (pl) | 2010-08-31 |
| US20080069843A1 (en) | 2008-03-20 |
| AU783508B2 (en) | 2005-11-03 |
| ES2222152T3 (es) | 2005-02-01 |
| JP2001186874A (ja) | 2001-07-10 |
| BR0006291A (pt) | 2001-11-27 |
| HUP0005010A2 (en) | 2002-06-29 |
| EP1112747A1 (en) | 2001-07-04 |
| PL344851A1 (en) | 2001-07-02 |
| JP5745731B2 (ja) | 2015-07-08 |
| ATE269104T1 (de) | 2004-07-15 |
| TR200401569T4 (tr) | 2004-07-21 |
| HU226192B1 (en) | 2008-06-30 |
| US20010021386A1 (en) | 2001-09-13 |
| AU7245300A (en) | 2001-07-05 |
| HU0005010D0 (cg-RX-API-DMAC7.html) | 2001-02-28 |
| HUP0005010A3 (en) | 2004-07-28 |
| CA2329676A1 (en) | 2001-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080069843A1 (en) | Salmonella vaccine | |
| JP2002521345A (ja) | 鳥類病原体を制御するため生きた弱毒化サルモネラワクチン | |
| US20080254062A1 (en) | Use of an avirulent bordetella mutant as a live vaccine vector | |
| US7045122B2 (en) | Salmonella vaccine | |
| HUP0201117A2 (en) | Attenuated microorganisms for the treatment of infection | |
| Stevenson et al. | Use of a rationally attenuated Bordetella bronchiseptica as a live mucosal vaccine and vector for heterologous antigens | |
| AU776864B2 (en) | Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of DNA methylation in bacterial virulence | |
| KR100602460B1 (ko) | 백신용 약독화 생박테리아 | |
| US20090263419A1 (en) | Live attenuated bacterial vaccine | |
| WO2025151964A1 (en) | Genetically modified bacteria having stable mutations without the requirement of antibiotic markers, and systems and methods for generating same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| GB | Transfer or rights |